NEW YORK, Dec. 6, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) alleging that the Company violated federal securities laws.
Class Period: March 10, 2021 to October 4, 2022
Lead Plaintiff Deadline: January 9, 2023
No obligation or cost to you.
Learn more about your recoverable losses in EIGR:
Eiger BioPharmaceuticals, Inc. NEWS - EIGR NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Eiger BioPharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger's clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ("EUA") for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Eiger you have until January 9, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Eiger securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the EIGR lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/eiger-biopharmaceuticals-class-action-submission-form?id=34269&from=4.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE The Klein Law Firm
These press releases may also interest you